This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.
ADME PK

Advanced Bioanalytical Method Development and Sample Analysis Service

Cyprotex offer advanced bioanalytical method development under our portfolio of services. Our state of the art instrumentation, in combination with our experienced bioanalytical scientists, provides a superior, high quality service.

What can Cyprotex offer?

  • State of the art highly sensitive instrumentation (AB Sciex QTRAP® 5500 and AB Sciex TripleTOF® 6600, Waters Xevo® TQ-MS and Waters Xevo® G2-S QTof LC-MS/MS systems).
  • Highly trained and experienced bioanalytical scientists with over 120 years combined experience.
  • Networked data management system and data archive / back-up facilities.
  • Close customer consultation and interaction.

Service Offering

  • Advanced bioanalytical method development and qualification.
  • Bioanalytical method transfer.
  • Small molecules and peptide bioanalysis (proteins and other biotherapeutics can be supported on request).
Bioanalysis is a term generally used to describe the quantitative measurement of a compound (drug) or their metabolite in biological fluids, primarily blood, plasma, serum, urine or tissue extracts.

1Pandey S, et al., (2010) Pharm Methods 1(1); 14-24

Instrumentation

LC Systems

  • 11 x Waters Acquity UPLC (1 with 2D technology)
  • 4 x Agilent 1290 Infinity 2D uHPLC
  • 2 x Agilent 1200 uHPLC

GC Systems

  • 1 x Waters Atmospheric Pressure Gas Chromatography (APGC)

UV and Radiochem Detectors

  • 2 x Acquity UPLC PDA detectors
  • 1 x Agilent DAD
  • 1 x LabLogic β-RAM® radiochemical detector

Mass Spectrometers

  • 11 x Waters Xevo® TQ-MS
  • 4 x Applied Biosystems Sciex QTRAP® 5500
  • 2 x Applied Biosystems Sciex TripleTOF® 6600
  • 1 x Waters Xevo® G2-S QTof
  • 2 x Agilent 6410
  • 1 x Waters QDa

All our LC-MS/MS systems are protected by an uninterrupted power supply system ensuring power input fluctuations are smoothed out/reduced and the systems are supported by a limited battery backup power supply in case of mains power failure.

Cyprotex has expertise in a wide range of bioanalytical techniques including:

  • sensitive small molecule detection and quantification
  • high resolution metabolite ID studies
  • peptide biotherapeutic bioanalysis

Data

Advanced bioanalytical method development service offering

 
Bioanalytical Method Development Service

Understanding the chemistry of your compound is important for designing the method development studies. The service consists of 3 main steps:

Step 1: MS/MS optimization (if preferred method of detection is mass spectrometry)
Step 2: Chromatographic method development
Step 3: Sample preparation

 

Advanced Bioanalytical Method Development Service

Our advanced bioanalytical method development service is a non-GLP service which can evaluate any of the following parameters to assess robustness of the bioanalytical method. These parameters can be tailored based on customer requirements.

  • Linearity and sensitivity
  • Accuracy and precision
  • Selectivity
  • Matrix effects
  • Stability (freeze thaw, short term, post preparative)
  • Recovery
Data are presented in a written report.
Example reports are available on request.

Q&A

How would you approach a bioanalytical method development study?

Cyprotex feel that it is important to work closely with clients for these studies. It is vital to identify specific customer requirements or issues prior to initiating the work. For example, the customer may have a need to detect compounds at a particular level for future routine studies or they may be aware of specific issues such as light sensitivity or stability. It is beneficial to have as much information as possible from the customer regarding the compound e.g., structure, physicochemical properties or previously developed methods. This will help us to identify the optimal conditions with respect to chromatographic columns and mobile phase gradients.

Method development is performed in 4 phases. The client will be consulted at each stage of the process.

  1. MS/MS Optimization – If the preferred method of detection is mass spectrometry, initially, the compound is optimized using either ESI (electrospray) or APCI (atmospheric pressure chemical ionization) in both positive and negative modes. The purpose of this step is to characterize the precursor and product transition parameters required for sample analysis.
  2. Chromatographic Method Development – The compound is assessed using established Cyprotex chromatographic methods based on C18 reverse phase chromatography. Calibration standards are prepared in a ‘matrix free’ environment to assess the sensitivity and linearity of the compound under the established conditions. If the initial investigation identifies that the existing Cyprotex chromatographic method is not suitable for the compound then a specific bioanalytical method is developed. Depending on the results obtained in the initial investigation and the structural and physicochemical nature of the compound, a number of different column chemistries (e.g., phenyl, HILIC or C8) and mobile phases can be assessed. Alternatively, should simple 1D chromatography not provide sufficient selectivity, a number of 2D methods can be employed to generate a more robust methodology. Once an appropriate method has been developed, matrix free calibration standards are used to assess the sensitivity of the compound response at this stage.
  3. Sample Preparation – For small molecule analysis in plasma, protein precipitation is the most convenient and cost effective method of sample preparation. Therefore, protein precipitation is assessed for its suitability as an initial assessment. Urine is diluted with high purity water and injected directly onto the LC-MS/MS system. Alternative matrices can be investigated. Two calibration standards (low and high concentrations) are selected to assess recovery. If the initial investigation identifies that protein precipitation is not a suitable method for sample preparation then alternative methods (e.g., SPE, SLE, PL depletion etc.) may be investigated. The recovery does not need to be 100% but the extent of the recovery of an analyte should be consistent, linear, precise and reproducible. For peptides and other biotherapeutics a more structured sample preparation approach is adopted in consultation with the client.
  4. Linearity in Matrix – Once a suitable extraction method is identified, calibration standards are prepared in the relevant matrix and analysed to confirm linearity. QC samples are analyzed at low, medium and high concentrations to check the validity of the standard curve.

Describe the advanced bioanalytical method development procedure.

This may evaluate linearity and sensitivity, accuracy and precision, inter and intra batch variability, selectivity, matrix effects and stability. The process can be customized depending on specific customer requirements.

How are data reported to the customer?

For the method development studies, details of the protocol for the bioanalytical method along with any supporting data generated during the development process is presented as a written report.

Example reports are available on request.

Do you offer this service to GLP?

Although these studies are not performed to GLP they do follow the current regulatory guidance;

Draft FDA Guidance for Industry for Bioanalytical Method Validation (Sept 2013)2.

Download

EMA Guideline on Bioanalytical Method Validation which came into effect in February 20123.

Download

References

1 Pandey S, et al. (2010) Bioanalysis in drug discovery and development. Pharm Methods 1(1); 14-24
2 Draft FDA Guidance for Industry for Bioanalytical Method Validation (Sept 2013)
3 EMA Guideline on Bioanalytical Method Validation (Feb 2012)

Request a Quote
Speak to a Scientist
Product sheet ADME-Tox Guides Pricing & Discounts

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close